1
|
Vodicka P, Benesova K, Janikova A, Prochazka V, Belada D, Mocikova H, Steinerova K, Duras J, Karban J, Hanackova V, Sykorova A, Obr A, Trneny M. POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE REAL WORLD. Hematol Oncol 2021. [DOI: 10.1002/hon.43_2881] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- P Vodicka
- Charles University and General University Hospital First Department of Medicine Prague Czech Republic
| | - K Benesova
- Charles University and General University Hospital First Department of Medicine Prague Czech Republic
| | - A Janikova
- Faculty of Medicine, Masaryk University and University Hospital Department of Haematology and Oncology Brno Czech Republic
| | - V Prochazka
- Faculty of Medicine and Dentistry, Palacky University and University Hospital Department of Haemato‐Oncology Olomouc Czech Republic
| | - D Belada
- Faculty of Medicine, Charles University and University Hospital 4th Department of Internal Medicine ‐ Haematology Hradec Kralove Czech Republic
| | - H Mocikova
- Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady Department of Internal Medicine – Haematology Prague Czech Republic
| | - K Steinerova
- Faculty of Medicine, Charles University and University Hospital Department of Haemato‐Oncology Pilsen Czech Republic
| | - J Duras
- Medical Faculty of the Ostrava University and University Hospital Department of Haematology Ostrava Czech Republic
| | - J Karban
- Charles University and General University Hospital First Department of Medicine Prague Czech Republic
| | - V Hanackova
- Faculty of Medicine and Dentistry, Palacky University and University Hospital Department of Haemato‐Oncology Olomouc Czech Republic
| | - A Sykorova
- Faculty of Medicine, Charles University and University Hospital 4th Department of Internal Medicine ‐ Haematology Hradec Kralove Czech Republic
| | - A Obr
- Faculty of Medicine and Dentistry, Palacky University and University Hospital Department of Haemato‐Oncology Olomouc Czech Republic
| | - M Trneny
- Charles University and General University Hospital First Department of Medicine Prague Czech Republic
| |
Collapse
|
2
|
Mocikova H, Pytlik R, Benesova K, Janikova A, Duras J, Sykorova A, Steinerova K, Prochazka V, Campr V, Belada D, Dlouha J, Trneny M. PERIPHERAL T‐CELL LYMPHOMAS INVOLVING CENTRAL NERVOUS SYSTEM: A REPORT FROM THE CZECH LYMPHOMA STUDY GROUP REGISTRY. Hematol Oncol 2021. [DOI: 10.1002/hon.132_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- H. Mocikova
- University Hospital Kralovske Vinohrady and Third Faculty of Medicine Charles University Department of Haematology Prague Czech Republic
| | - R. Pytlik
- Institute of Haematology and Blood Transfusion Cell Therapy Department Prague Czech Republic
| | - K. Benesova
- Charles University General Hospital First Department of Medicine Department of Hematology Prague Czech Republic
| | - A. Janikova
- University Hospital Brno Department of Hematology and Oncology Brno Czech Republic
| | - J. Duras
- University Hospital and Faculty of Medicine Department of Hemato‐Oncology Ostrava Czech Republic
| | - A. Sykorova
- University Hospital and Faculty of Medicine 4th Department of Internal Medicine– Hematology Hradec Kralove Czech Republic
| | - K. Steinerova
- University Hospital Department of Clinical Hematology Pilsen Czech Republic
| | - V. Prochazka
- Faculty of Medicine and Dentistry Palacky University Department of Haemato‐Oncology Olomouc Czech Republic
| | - V. Campr
- University Hospital Motol Institute of Pathology and Molecular Medicine Prague Czech Republic
| | - D. Belada
- University Hospital and Faculty of Medicine 4th Department of Internal Medicine– Hematology Hradec Kralove Czech Republic
| | - J. Dlouha
- Czech Lymphoma Study Group Registry Data Management Office Prague Czech Republic
| | - M. Trneny
- Charles University General Hospital First Department of Medicine Department of Hematology Prague Czech Republic
| |
Collapse
|
3
|
Sykorova A, Mocikova H, Lukasova M, Koren J, Stepankova P, Prochazka V, Belada D, Klaskova K, Gaherova L, Chroust K, Buresova L, Markova J. Outcome of elderly patients with classical Hodgkin’s lymphoma. Leuk Res 2020; 90:106311. [DOI: 10.1016/j.leukres.2020.106311] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2019] [Revised: 01/18/2020] [Accepted: 01/22/2020] [Indexed: 11/27/2022]
|
4
|
Trneny M, Polgarova K, Janikova A, Belada D, Prochazka V, Duras J, Mocikova H, Steinerova K, Campr V, Blahovcova P, Petrova M, Zogala D, Ptacnik V. IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) PATIENTS ACHIEVING PET NEGATIVITY AFTER IMMUNOCHEMOTHERAPY? Hematol Oncol 2019. [DOI: 10.1002/hon.77_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Trneny
- Ist Dept Med; Charles University General Hospital; Praha Czech Republic
| | - K. Polgarova
- Ist Dept Med; Charles University General Hospital; Praha Czech Republic
| | - A. Janikova
- Dept Hemato-Oncology; University Hospital Brno; Brno Czech Republic
| | - D. Belada
- Dept Hematology; University Hospital; Hradec Kralove Czech Republic
| | - V. Prochazka
- Dept Hematology; University Hospital; Olomouc Czech Republic
| | - J. Duras
- Dept Hematology; University Hospital; Ostrava Czech Republic
| | - H. Mocikova
- Dept Hematology; University Hospital Kralovske Vinohrady; Praha Czech Republic
| | - K. Steinerova
- Dept Hematology; University Hospital; Plzen Czech Republic
| | - V. Campr
- Dept Pathology; University Hospital Motol; Praha Czech Republic
| | - P. Blahovcova
- Data Center; Czech Lymphoma Study Group; Praha Czech Republic
| | - M. Petrova
- Data Center; Czech Lymphoma Study Group; Praha Czech Republic
| | - D. Zogala
- Dept Nuclear Medicine; Charles University General Hospital; Praha Czech Republic
| | - V. Ptacnik
- Dept Nuclear Medicine; Charles University General Hospital; Praha Czech Republic
| |
Collapse
|
5
|
Mocikova H, Gaherova L, Fayette D, Jurickova V, Horacek J, Kozak T. COGNITIVE IMPAIRMENT AFTER 6 AND 12 MONTHS OF HODGKIN LYMPHOMA TREATMENT. Hematol Oncol 2019. [DOI: 10.1002/hon.180_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- H. Mocikova
- 1Internal Hematology Clinic; University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - L. Gaherova
- 1Internal Hematology Clinic; University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - D. Fayette
- National Institute of Mental Health, Klecany, and Third faculty of Medicine; National Institute of Mental Health, Klecany, and Third faculty of Medicine; Klecany Czech Republic
| | - V. Jurickova
- National Institute of Mental Health, Klecany, and Third faculty of Medicine; National Institute of Mental Health, Klecany, and Third faculty of Medicine; Klecany Czech Republic
| | - J. Horacek
- National Institute of Mental Health, Klecany, and Third faculty of Medicine; National Institute of Mental Health, Klecany, and Third faculty of Medicine; Klecany Czech Republic
| | - T. Kozak
- 1Internal Hematology Clinic; University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| |
Collapse
|
6
|
Janikova A, Chloupkova R, Campr V, Kopalova N, Klener P, Benesova K, Hamouzova J, Belada D, Sykorova A, Prochazka V, Pirnos J, Duras J, Mocikova H, Michalka J, Trneny M. PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAPY INITIATION IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP DATABASE. Hematol Oncol 2019. [DOI: 10.1002/hon.83_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Janikova
- Department of Internal Medicine - Hematology nad Oncology; Masaryk University and Univesity Hospital Brno; Brno Czech Republic
| | - R. Chloupkova
- Institute of Biostatistics and Analyses; Faculty of Medicine Masaryk University Brno; Brno Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine; 2nd Faculty of Medicine, Charles University Prague and Motol University Hospital; Prague Czech Republic
| | - N. Kopalova
- Department of Internal Medicine - Hematology nad Oncology; Masaryk University and Univesity Hospital Brno; Brno Czech Republic
| | - P. Klener
- First Internal Clinic - Clinic of Hematology; General University Hospital and First Faculty of Medicine, Charles University; Prague Czech Republic
| | - K. Benesova
- First Internal Clinic - Clinic of Hematology; General University Hospital and First Faculty of Medicine, Charles University; Prague Czech Republic
| | - J. Hamouzova
- First Internal Clinic - Clinic of Hematology; General University Hospital and First Faculty of Medicine, Charles University; Prague Czech Republic
| | - D. Belada
- The 4th Department of Internal Medicine - Hematology; University Hospital and Faculty of Medicine in Hradec Králové Charles University; Hradec Kralove Czech Republic
| | - A. Sykorova
- The 4th Department of Internal Medicine - Hematology; University Hospital and Faculty of Medicine in Hradec Králové Charles University; Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hemato-Oncology; Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - J. Pirnos
- Department of Oncology; Hospital Ceske Budejovice; Ceske Budejovice Czech Republic
| | - J. Duras
- Department of Haematooncology; University Hospital Ostrava and Medical Faculty of the Ostrava University; Ostrava Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady Prague and Third Faculty of Medicine, Charles University Prague; Prague Czech Republic
| | - J. Michalka
- Department of Internal Medicine - Hematology nad Oncology; Masaryk University and Univesity Hospital Brno; Brno Czech Republic
| | - M. Trneny
- First Internal Clinic - Clinic of Hematology; General University Hospital and First Faculty of Medicine, Charles University; Prague Czech Republic
| |
Collapse
|
7
|
Janikova A, Chloupkova R, Klener P, Benesova K, Campr V, Belada D, Sykorova A, Prochazka V, Kopalova N, Hamouzova J, Pirnos J, Duras J, Mocikova H, Trneny M. T-CELL LYMPHOMA IN THE ELDERLY PATIENTS. WHO IS YOUNG, OLD, AND ELDERLY? Hematol Oncol 2019. [DOI: 10.1002/hon.145_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Janikova
- Department of Internal Medicine - Hematology nad Oncology; Univesity Hospital Brno; Brno Czech Republic
| | - R. Chloupkova
- Institute of Biostatistics and Analyses; Faculty of Medicine Masaryk University Brno; Brno Czech Republic
| | - P. Klener
- 1st Internal Clinic- Clinic of Hematology; First Medical Faculty, Charles University, and General University Hospital; Prague Czech Republic
| | - K. Benesova
- 1st Internal Clinic- Clinic of Hematology; First Medical Faculty, Charles University, and General University Hospital; Prague Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine; 2nd Faculty of Medicine, Charles University and Faculty Hospital in Motol; Prague Czech Republic
| | - D. Belada
- 4th Department of Internal Medicine - Hematology; Charles University, Hospital and Faculty of Medicine; Hradec Králové Hradec Kralove Czech Republic
| | - A. Sykorova
- 4th Department of Internal Medicine - Hematology; Charles University, Hospital and Faculty of Medicine; Hradec Králové Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hemato-Oncology; University Hospital Olomouc; Olomouc Czech Republic
| | - N. Kopalova
- Department of Internal Medicine - Hematology nad Oncology; Univesity Hospital Brno; Brno Czech Republic
| | - J. Hamouzova
- 1st Internal Clinic- Clinic of Hematology; First Medical Faculty, Charles University, and General University Hospital; Prague Czech Republic
| | - J. Pirnos
- Department of Oncology; Hospital Ceske Budejovice; Ceske Budejovice Czech Republic
| | - J. Duras
- Department of Haematooncology; University Hospital Ostrava and Medical Faculty of the Ostrava University; Ostrava Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady Prague and Third Faculty of Medicine, Charles University Prague; Prague Czech Republic
| | - M. Trneny
- 1st Internal Clinic- Clinic of Hematology; First Medical Faculty, Charles University, and General University Hospital; Prague Czech Republic
| |
Collapse
|
8
|
Obr A, Klener P, Belada D, Pytlik R, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Markova J, Campr V, Kodet R, Trneny M. MAINTENANCE RITUXIMAB IMPROVES SURVIVAL IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_69] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Obr
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - P. Klener
- First Medical Dept.; Charles University General Hospital in Prague; Prague 1 Czech Republic
| | - D. Belada
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - R. Pytlik
- First Medical Dept.; Charles University General Hospital in Prague; Prague 1 Czech Republic
| | - M. Simkovic
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - D. Salek
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - H. Mocikova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Prague 10 Czech Republic
| | - V. Prochazka
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - A. Janikova
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - J. Markova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Prague 10 Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine; Charles University Hospital in Motol, Prague, and Second Faculty of Medicine; Praha 5 Czech Republic
| | - R. Kodet
- Department of Pathology and Molecular Medicine; Charles University Hospital in Motol, Prague, and Second Faculty of Medicine; Praha 5 Czech Republic
| | - M. Trneny
- First Medical Dept.; Charles University General Hospital in Prague; Prague 1 Czech Republic
| |
Collapse
|
9
|
Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcová P, Janikova A, Markova J, Obr A, Berkova A, Vaskova M, Mejstrikova E, Campr V, Kubinyi J, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M. R-CHOP/R-HDAC AND RITUXIMAB MAINTENANCE RESULTS IN HIGH COMPLETE REMISSION RATE, MINIMAL RESIDUAL DISEASE NEGATIVITY, AND EXCELLENT SURVIVAL IN ELDERLY MCL PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Klener
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - E. Fronkova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - D. Belada
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - K. Forsterova
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - R. Pytlik
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - M. Kalinova
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - M. Simkovic
- Fourth Dept. of Internal Medicine-Hematology; Charles University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - D. Salek
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - H. Mocikova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - V. Prochazka
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - P. Blahovcová
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| | - A. Janikova
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - J. Markova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - A. Obr
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - A. Berkova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - M. Vaskova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - E. Mejstrikova
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - V. Campr
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - J. Kubinyi
- Institute of nuclear medicine; Charles University General Hospital in Prague; Prague Czech Republic
| | - R. Jaksa
- Institute of Pathology; Charles University Hospital and First Faculty of Medicine, Prague; Prague Czech Republic
| | - R. Kodet
- Institute of Pathology and Molecular Medicine; Charles University Hospital in Motol and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - K. Michalova
- Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - J. Trka
- CLIP, Dept. of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital Motol Prague; Prague Czech Republic
| | - M. Trneny
- First Dept. of Internal Medicine; Charles University General Hospital in Prague; Prague 2 Czech Republic
| |
Collapse
|
10
|
Janikova A, Campr V, Kopalova N, Benesova K, Belada D, Prochazka V, Duras J, Dlouha J, Mocikova H, Sykorova A, Brejcha M, Mayer J, Trneny M. Beyond rituximab maintenance. relapsing follicular lymphoma during or after end of rituximab maintenance: analysis of Czech Lymphoma Study Group (CLSG) database. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_117] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Janikova
- Department of Hematology and Oncology, Faculty of Medicine; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine; Charles University and Faculty Hospital in Motol, Prague; Prague Czech Republic
| | - N. Kopalova
- Department of Hematology and Oncology, Faculty of Medicine; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - K. Benesova
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| | - D. Belada
- 4th Department of Internal medicine-Hematology; Charles University Hospital and Faculty of Medicine, Hradec Králové; Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hematology; University Hospital Olomouc; Olomouc Czech Republic
| | - J. Duras
- Department of Clinical Hematology; Teaching Hospital Ostrava; Ostrava Czech Republic
| | - J. Dlouha
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady and Charles University, 3rd Faculty of Medicine, Prague; Prague Czech Republic
| | - A. Sykorova
- 4th Department of Internal medicine-Hematology; Charles University Hospital and Faculty of Medicine, Hradec Králové; Hradec Kralove Czech Republic
| | - M. Brejcha
- Department of Hematology; Hospital Novy Jicin; Novy Jicin Czech Republic
| | - J. Mayer
- Department of Hematology and Oncology, Faculty of Medicine; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - M. Trneny
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| |
Collapse
|
11
|
Janikova A, Campr V, Kopalova N, Benesova K, Belada D, Dlouha J, Duras J, Prochazka V, Mocikova H, Kubackova K, Sykorova A, Brejcha M, Mayer J, Trneny M. INCIDENCE AND OUTCOME OF PRIMARY EXTRANODAL FOLLICULAR LYMPHOMAS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Janikova
- Hematology and Oncology; University Hospital Brno; Brno Czech Republic
| | - V. Campr
- Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine; Charles University and Faculty Hospital in Motol; Prague Czech Republic
| | - N. Kopalova
- Hematology and Oncology; University Hospital Brno; Brno Czech Republic
| | - K. Benesova
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| | - D. Belada
- 4th Department of Internal medicine - Hematology; Charles University Hospital and Faculty of Medicine, Hradec Králové; Hradec Kralove Czech Republic
| | - J. Dlouha
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| | - J. Duras
- Department of Clinical Hematology; Teaching Hospital Ostrava; Ostrava Czech Republic
| | - V. Prochazka
- Department of Hematology; University Hospital Olomouc; Olomouc Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady and Charles University, 3rd Faculty of Medicine Prague; Prague Czech Republic
| | - K. Kubackova
- Department of Oncology, 2nd Faculty of Medicine; Charles University and Faculty Hospital in Motol, Prague; Prague Czech Republic
| | - A. Sykorova
- 4th Department of Internal medicine - Hematology; Charles University Hospital and Faculty of Medicine, Hradec Králové; Hradec Kralove Czech Republic
| | - M. Brejcha
- Department of Hematology; Hospital Novy Jicin; Novy Jicin Czech Republic
| | - J. Mayer
- Hematology and Oncology; University Hospital Brno; Brno Czech Republic
| | - M. Trneny
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital, Prague; Prague Czech Republic
| |
Collapse
|
12
|
Musilova K, Pavlasova G, Seda V, Cerna K, Vojackova E, Didi J, Pytlik R, Prochazka V, Prouzova Z, Zlamalikova L, Mocikova H, Jarosova M, Evans A, Zent C, Kren L, Trneny M, Mayer J, Janikova A, Mraz M. DOWN-REGULATION OF MIR-150 AND UP-REGULATION OF ITS TARGET FOXP1 IS ASSOCIATED WITH TRANSFORMATION OF FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- K. Musilova
- Department of Internal Medicine - Hematology and Oncology, Centre for Molecular Medicine; University Hospital Brno and Faculty of Medicine MU and CEITEC MU; Brno Czech Republic
| | - G. Pavlasova
- Department of Internal Medicine - Hematology and Oncology, Centre for Molecular Medicine; University Hospital Brno and Faculty of Medicine MU and CEITEC MU; Brno Czech Republic
| | - V. Seda
- Department of Internal Medicine - Hematology and Oncology, Centre for Molecular Medicine; University Hospital Brno and Faculty of Medicine MU and CEITEC MU; Brno Czech Republic
| | - K. Cerna
- Department of Internal Medicine - Hematology and Oncology, Centre for Molecular Medicine; University Hospital Brno and Faculty of Medicine MU and CEITEC MU; Brno Czech Republic
| | - E. Vojackova
- Department of Internal Medicine - Hematology and Oncology, Centre for Molecular Medicine; University Hospital Brno and Faculty of Medicine MU and CEITEC MU; Brno Czech Republic
| | - J. Didi
- Centre for Molecular Medicine; CEITEC MU; Brno Czech Republic
| | - R. Pytlik
- 1st Department of Medicine - Department of Haematology; General University Hospital and Charles University in Prague; Prague Czech Republic
| | - V. Prochazka
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - Z. Prouzova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - L. Zlamalikova
- Department of Pathology; University Hospital Brno; Brno Czech Republic
| | - H. Mocikova
- Department for Internal Medicine and Haematology; University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague; Prague Czech Republic
| | - M. Jarosova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - A. Evans
- Department of Pathology and Laboratory Medicine; University of Rochester Medical Center School of Medicine and Dentistry; Rochester USA
| | - C. Zent
- Division of Hematology/Oncology, Wilmot Cancer Institute; University of Rochester Medical Center; Rochester USA
| | - L. Kren
- Department of Pathology; University Hospital Brno; Brno Czech Republic
| | - M. Trneny
- 1st Department of Medicine - Department of Haematology; General University Hospital and Charles University in Prague; Prague Czech Republic
| | - J. Mayer
- Department of Internal Medicine - Hematology and Oncology; University Hospital Brno and Faculty of Medicine MU; Brno Czech Republic
| | - A. Janikova
- Department of Internal Medicine - Hematology and Oncology; University Hospital Brno and Faculty of Medicine MU; Brno Czech Republic
| | - M. Mraz
- Department of Internal Medicine - Hematology and Oncology, Centre for Molecular Medicine; University Hospital Brno and Faculty of Medicine MU and CEITEC MU; Brno Czech Republic
| |
Collapse
|
13
|
Janikova A, Lobello C, Kren L, Hermanova M, Sprlakova-Pukova A, Krejci J, Pospisilova S, Pytlik R, Dlouha J, Belada D, Prochazka V, Duras J, Mocikova H, Mayer J, Trneny M. cardiac lymphomas: Incidence and outcome in newly diagnosed non-Hodgkin's lymphomas. Analysis from the Czech lymphoma study group (CLSG) database. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_72] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Janikova
- Department of Internal Medicine - Hematology and Oncology; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - C. Lobello
- Center of molecular biology and gene therapy; CEITEC - Central European Institute of Technology Brno; Brno Czech Republic
| | - L. Kren
- Department of Pathology, University Hospital and Faculty of Medicine; Masaryk University Brno; Brno Czech Republic
| | - M. Hermanova
- 1st Department of Pathological Anatomy, University Hospital St Anne and Faculty of Medicine; Masaryk University Brno; Brno Czech Republic
| | - A. Sprlakova-Pukova
- Department of Radiology, Faculty of Medicine; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - J. Krejci
- 1st Dept of Internal Medicine-Cardiology, University Hospital St Anne and Faculty of Medicine; Masaryk University Brno; Brno Czech Republic
| | - S. Pospisilova
- Center of molecular biology and gene therapy; CEITEC - Central European Institute of Technology Brno; Brno Czech Republic
| | - R. Pytlik
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital; Prague, Prague Czech Republic
| | - J. Dlouha
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital; Prague, Prague Czech Republic
| | - D. Belada
- 4th Department of Internal medicine - Hematology; Charles University Hospital and Faculty of Medicine Hradec Králové; Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hematology; University Hospital Olomouc; Olomouc Czech Republic
| | - J. Duras
- Department of Clinical Hematology; Teaching Hospital Ostrava; Ostrava Czech Republic
| | - H. Mocikova
- Internal Clinic of Haematology; University Hospital Kralovske Vinohrady; Prague, Prague Czech Republic
| | - J. Mayer
- Department of Internal Medicine - Hematology and Oncology; Masaryk University and University Hospital Brno; Brno Czech Republic
| | - M. Trneny
- 1st Department of Medicine, First Medical Faculty; Charles University, and General University Hospital; Prague, Prague Czech Republic
| |
Collapse
|
14
|
Klener P, Salek D, Mocikova H, Blahovcova P, Pytlik R, Janikova A, Prochazka V, Campr V, Boudova L, Jaksa R, Kodet R, Trneny M. RITUXIMAB MAINTENANCE AFTER NORDIC PROTOCOL (R-MAXICHOP/HD-ARAC/ASCT) SIGNIFICANTLY PROLONGS SURVIVAL IN YOUNG MANTLE CELL LYMPHOMA PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Klener
- First Dept. of Internal Medicine; Charles University General Hospital and First Faculty of Medicine; Prague Czech Republic
| | - D. Salek
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - H. Mocikova
- Dept. of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine; Charles University, Prague; Prague Czech Republic
| | - P. Blahovcova
- First Dept. of Internal Medicine; Charles University General Hospital and First Faculty of Medicine; Prague Czech Republic
| | - R. Pytlik
- First Dept. of Internal Medicine; Charles University General Hospital and First Faculty of Medicine; Prague Czech Republic
| | - A. Janikova
- Dept. of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic
| | - V. Prochazka
- Dept. of Hemato-Oncology, Faculty of Medicine and Dentistry; Palacky University and University Hospital Olomouc; Olomouc Czech Republic
| | - V. Campr
- Dept. of Pathology and Molecular Medicine; Charles University Hospital in Motol, and Second Faculty of Medicine, Prague; Prague Czech Republic
| | - L. Boudova
- Biopticka laborator, Biopticka laborator s.r.o; Plzen Czech Republic
| | - R. Jaksa
- Institute of Pathology; Charles University General Hospital and First Faculty of Medicine, Prague; Prague Czech Republic
| | - R. Kodet
- Institute of Pathology; Charles University General Hospital and First Faculty of Medicine, Prague; Prague Czech Republic
| | - M. Trneny
- First Dept. of Internal Medicine; Charles University General Hospital and First Faculty of Medicine; Prague Czech Republic
| |
Collapse
|
15
|
Benesova K, Janikova A, Belada D, Prochazka V, Pytlik R, Mocikova H, Sykorova A, Campr V, Blahovcova P, Trneny M. SIMULTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT THE DIAGNOSIS HAS SIMILAR OUTCOME AS DLBCL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- K. Benesova
- 1st Department of Internal Medicine-Department of Hematology; First Faculty of Medicine and General Teaching Hospital; Prague Czech Republic
| | - A. Janikova
- Department of Hematology and Oncology; University Hospital Brno; Brno Czech Republic
| | - D. Belada
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - V. Prochazka
- Department of Hemato-Oncology; Faculty of Medicine and Dentistry; Olomouc Czech Republic
| | - R. Pytlik
- 1st Department of Internal Medicine-Department of Hematology; First Faculty of Medicine and General Teaching Hospital; Prague Czech Republic
| | - H. Mocikova
- Department of Clinical Hematology; University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine; Prague 10 Czech Republic
| | - A. Sykorova
- 4th Department of Internal Medicine-Hematology; University Hospital and Faculty of Medicine; Hradec Kralove Czech Republic
| | - V. Campr
- Institute of Pathology; University Hospital Motol; Prague 5 Czech Republic
| | - P. Blahovcova
- 1st Department of Internal Medicine-Department of Hematology; First Faculty of Medicine and General Teaching Hospital; Prague Czech Republic
| | - M. Trneny
- 1st Department of Internal Medicine-Department of Hematology; First Faculty of Medicine and General Teaching Hospital; Prague Czech Republic
| |
Collapse
|
16
|
Cheah C, George A, Giné E, Chiappella A, Kluin-Nelemans H, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer R, Ritchie D, Arcaini L, Williams M, Dreyling M, Seymour J. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24:2119-23. [DOI: 10.1093/annonc/mdt139] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Havranek O, Spacek M, Hubacek P, Mocikova H, Markova J, Trneny M, Kleibl Z. Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma. Neoplasma 2011; 58:392-5. [PMID: 21744992 DOI: 10.4149/neo_2011_05_392] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Checkpoint kinase 2 gene (CHEK2) codes for an important mediator of DNA damage response pathway. Mutations in the CHEK2 gene increase the risk of several cancer types, however, their role in Hodgkin lymphoma (HL) has not been studied so far. The most frequent CHEK2 alterations (including c.470T>C; p.I157T) cluster into the forkhead-associated (FHA) domain-coding region of the CHEK2 gene. We performed mutation analysis of the CHEK2 gene segment coding for FHA domain using denaturing high-performance liquid chromatography in 298 HL patients and analyzed the impact of characterized CHEK2 gene variants on the risk of HL development and progression-free survival (PFS). The overall frequency of CHEK2 alterations was significantly higher in HL patients (17/298; 5.7%) compared to the previously analyzed non-cancer controls (19/683; 2.8%; p= 0.04). Presence of any alteration within the analyzed region of the CHEK2 gene was associated with increased risk of HL development (OR = 2.11; 95% CI = 1.08 - 4.13; p= 0.04). The most frequent I157T mutation was found in 4.0% of HL patients and 2.5% of controls (p = 0.22), however, the frequency of 5 other alterations (excluding I157T) was significantly higher in HL cases and associated with increased risk of HL development (OR = 5.81; 95% CI = 1.12 - 30.12; p= 0.03). PFS in HL patients did not differ between CHEK2 mutation carriers and non-carriers. The predominant I157T mutation together with other alterations in its proximity represent moderate genetic predisposition factor increasing the risk of HL development.
Collapse
Affiliation(s)
- O Havranek
- Department of Medicine--Department of Hematology, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic
| | | | | | | | | | | | | |
Collapse
|
18
|
Mocikova H, Obrtlikova P, Vackova B, Trneny M. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol 2010; 21:1222-1227. [DOI: 10.1093/annonc/mdp522] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Feltl D, Markova J, Mocikova H, Dedeckova K, Kozak T. Prognostic impact of bone involvement in Hodgkin lymphoma. Neoplasma 2008; 55:96-100. [PMID: 18237246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The purpose of the study is to determine incidence and prognostic impact of osseous Hodgkin lymphoma (HL). Between 1997 and 2004, 198 patients with HL were treated at our institution. Advanced stages and nodular sclerosis histology prevailed. All patients were treated according to protocols of the German Hodgkin Study Group (GHSG). After minimum follow-up of 24 months, we retrospectively analyzed the incidence of osseous HL, treatment response and parameters of survival. We recorded 14 cases of osseous HL (7 %), always with concurrent nodal disease. Axial skeleton was most frequently involved. Eleven patients (78,5 %) achieved complete remission and three (21,5 %) progressed primarily. The patients with osseous HL had significantly lower 2-year freedom from treatment failure than the patients without bone involvement (71,4 and 92,7 %, respectively, p=0,004), with no significant difference in 2-year overall survival (85,7 and 95 %, respectively, p=0,14). On multivariate analysis, advanced stage was the only independent adverse prognostic factor. In conclusion, bone involvement is a relatively common finding in HL and is not an independent adverse prognostic factor.
Collapse
Affiliation(s)
- D Feltl
- Department of Oncology, University Hospital Ostrava, Czech Republic.
| | | | | | | | | |
Collapse
|
20
|
Osmancik P, Bednar F, Mocikova H, Stros P, Widimsky P. Mo-P2:204 The role of platelet activity in patients with patent versus occluded coronary artery bypass grafts. Prague-4 trial subanalysis. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)80338-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|